Biotech News

OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026

Bio-Reference Laboratories (BRLI)Bio-Reference Laboratories2026-04-21 20:05 ESTEarnings

BRLI (BRLI) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is brli.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

BRLIBio-Reference Laboratories2026-07-23 16:30 EST

OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026

BRLIBio-Reference Laboratories2026-06-15 12:00 EST

Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026

BRLIBio-Reference Laboratories2026-04-30 12:30 EST

OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China

BRLIBio-Reference Laboratories2026-04-28 20:05 EST

OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results

BRLIBio-Reference Laboratories2026-04-22 12:00 EST

OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas

BRKRBruker2026-07-24 20:01 EST

Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast

NAMSNewAmsterdam Pharma2026-07-24 12:00 EST

NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)

IMVTImmunovant2026-07-23 20:05 EST

Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

EHCEncompass Health Corporation2026-07-23 12:00 EST

Encompass Health increases and declares dividend on common stock

IKTInhibikase Therapeutics2026-07-23 12:00 EST

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

Bio-Reference Laboratories

Bio-Reference Laboratories is a clinical laboratory and diagnostic services company focused on testing and related healthcare services. Its role is to process and interpret lab work rather than develop therapeutics.

Recent company news

Stock data

Close
Market cap
Exchange
NASDAQ
Sector
MedTech
Location
United States